[1] 谢莉娜,卢山.2型糖尿病肾病患者骨密度分析[J].医学影像学杂志,2007,17(12):1373-1375. [2] 苏木珍.2型糖尿病肾病与无肾病患者骨密度及血清PTH变化随机对照研究[J].白求恩医学杂志,2017,15 (2):192-193. [3] 王雪,李英.维生素D延缓糖尿病肾病的研究进展[J].临床荟萃,2018,33(3):267-270. [4] Zheng JM, Yao GH, Cheng Z, et al. Pathogenic role of mast cells in the development of diabetic nephropathy: a study of patients at different stages of the disease[J] .Diabetologia,2012,55(3): 801-811. [5] Pike JW, Meyer MB, Bishop KA. Regulation of target gene expression by the vitamin D receptor-an update on mechanisms[J]. Rev Endocr Metab Disord,2012,13(1):45-55. [6] Rolvien T, Krause M, Jeschke A, et al. Vitamin D regulates osteocyte survival and perilacunar remodeling in human and murine bone[J]. Bone,2017,103: 78-87. [7] Leary PF, Zamfirova I, Au J, et al. Effect of latitude on vitamin D levels[J].J Am Osteopath Assoc, 2017,117 (7):433-439. [8] 毛琳,李莉.2型糖尿病患者血清维生素 D水平及其影响因素[J].中国医科大学学报,2017,46(1):68-71. [9] 曾艳,赵韶静,李正东. 2型糖尿病肾病患者25-羟维生素D水平变化及意义[J]. 临床肾脏病杂志,2018,18(12):770-774. [10] Peng Y, Li LJ. Serum 25-hydroxyvitamin D level and diabetic nephropathy in patients with type 2 diabetes mellitus[J].Int Urol Nephrol, 2015, 47(6):983- 989. [11] Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, et al.Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among US adults[J].J Bone Miner Res,2009,24(5): 935-942. [12] Ishimura E, Nishizawa Y, Inaba M, et al. Serum levels of 1,25-dihydroxyvitamin D,24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure[J]. Kidney Int,1999,55(3):1019-1027. [13] Elder GJ, Mackun K.25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease [J]. J Bone Miner Res,2006,21(11):1778-1784. [14] 原晶,贾璞,唐海,等. 2型糖尿病患者血清 25-羟维生素D水平及其与骨密度的关系[J].中华骨质疏松和骨矿盐疾病杂志,2018,11(2):149-153. |